Last Updated: November 29, 2023 Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19 positive relapsed or refractory acute myeloid leukemia.